- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02012413
Effect of Pulsed Signal Therapy in Patella Chondromalacia
Effect of Pulsed Signal Therapy in Patella Chondromalacia. Randomized Prospective Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study was approved by the Research Ethics Committee of the Clinical Hospital (Hospital das Clinicas), University of São Paulo (Universidade de São Paulo - USP) under number 0253/11.
This patient population is estimated to a total of 40 knees, with the patients meeting the following inclusion criteria:
- aged between 20 and 50 years;
- male or female;
- patellofemoral pain syndrome without tibiofemoral and trochlear chondral degeneration according to magnetic resonance imaging (MRI);
- presence of patellar chondropathy confirmed by MRI;
- not having started using direct action drugs on the cartilage in the last 6 months;
- absence of prior surgery on the studied knee;
- absence of invasive procedures, such as knee infiltration, in the previous 12 months;
- absence of disease in the contralateral limb that would cause an excessive burden on the studied limb; and
- absence of contraindications to performing PST, including a pacemaker, cancer, infectious disease activity, severe heart failure, arrhythmias, angina, epilepsy and pregnancy.
The presence of patellofemoral pain is identified by anamnesis and physical examination performed by knee surgeons with more than 10 years' experience. The presence of all of the following criteria is required for diagnosis: typical complaint of anterior knee pain with a duration longer than 3 months (when going up or down stairs, squatting, remaining for long periods with bent knees), pain on palpation of the patellar articular surface and pain on patellar compression (reproducing the patient's complaint).
After inclusion in the study, all of the patients will be instructed (for the duration of the study) not to use drugs with a direct action on the cartilage (e.g., chondroprotectors, such as glucosamine and chondroitin) to avoid confounding biases regarding the effects of the treatments. No patients will be included who had started using these drugs in the previous 6 months to avoid the initial effect of this treatment being a confounder in terms of clinical improvement.
The study is designed so that the patient and the orthopedist evaluating the clinical outcome do not know to which group the patient belongs (i.e., a double-blind study).
After patient inclusion and signing of the terms of free and informed consent, the patients will be randomized by a computer into 2 equal groups, i.e., the control and PST groups. The patients with both knees included in the study will receive randomization for the right knee, and the left will be automatically allocated into the other group. This method was selected to best demonstrate any differences between groups. The final distribution of patients into groups will be therefore not equalized.
PST application will be then directed to the patellofemoral joint. The PST application protocol is as follows: 9 daily 1-hour applications, with 5 in the first week, a break for the weekend, and 4 more the following week.
The control group patients will be submitted to placebo PST treatment with the same protocol and the device connected not generating magnetic pulses. The device operates silently, and it is not possible for the patient to determine whether they are receiving the placebo or treatment, thus maintaining patient blinding. For patients with both knees included, 9 sessions of the treatment are performed on one side and 9 more sessions of the placebo on the other.
All of the participants are instructed to maintain their usual level of physical activity.
The Kujala score will be taken after 3, 6 and 12 months in both groups. If superiority of the PST group is observed, it was decided for ethical reasons that the placebo group should receive the PST treatment and would again be followed up for 1-year post-treatment, with the Kujala score ascertained at 3, 6 and 12 months.
A sample of approximately 20 patients in each group was used for an alpha of 5% and beta of 20%. An effect size of 8 to 10 between groups was sought and is considered clinically significant in terms of Kujala score.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Sao Paulo, Brazil, 05403-010
- Hospital das Clínicas - Universty of São Paulo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patellofemoral pain syndrome without tibiofemoral and trochlear chondral degeneration according to magnetic resonance imaging (MRI);
- presence of patellar chondropathy confirmed by MRI;
- not having started using direct action drugs on the cartilage in the last 6 months;
- absence of prior surgery on the studied knee;
- absence of invasive procedures, such as knee infiltration, in the previous 12 months;
- absence of disease in the contralateral limb that would cause an excessive burden on the studied limb; and
- absence of contraindications to performing PST, including a pacemaker, cancer, infectious disease activity, severe heart failure, arrhythmias, angina, epilepsy and pregnancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: PST group
roughly 20 patients will be treated with PST protocol, outcomes will be Kujala score improvement at 3, 6 and 12 months.
|
PST application is a painless over-the-skin eletromagnetic field application.
9 sessions of application of electromagnetic therapy - PST - during 60 minutes
Other Names:
|
Placebo Comparator: Control group
roughly 20 patients will be submitted to a placebo PST protocol, outcomes will be Kujala score improvement at 3, 6 and 12 months.
|
Placebo PST will be performed by applying the same device over the patient knee. The machine is not applying the PST but it appears to be on. In this way, patients are blinded to the intervation. 9 sessions of application of Sham PST - during 60 minutes
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical improvement - Kujala score
Time Frame: 12 months
|
A functional score (Kujala) will be performed before, at 3 months, at 6 months and at one year after PST intervention and placebo.
|
12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Adriana Lucia P Silva, B.Sc., M.Sc., University of Sao Paulo
- Principal Investigator: Riccardo G Gobbi, M.D., University of Sao Paulo
- Study Chair: Gilberto L Camanho, M.D., Ph.D, University of Sao Paulo
- Study Director: Marco K Demange, M.D., Ph.D, University of Sao Paulo
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012/50167-6
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patella Chondromalacia
-
University of VirginiaCompletedPatellofemoral Pain Syndrome | Chondromalacia PatellaUnited States
-
Cairo UniversityNot yet recruiting
-
Instituto Mexicano del Seguro SocialCompletedChondromalacia PatellaeMexico
-
Kayseri City HospitalCompletedChondromalacia PatellaeTurkey
-
Aarhus University HospitalNot yet recruitingPatella DysplasiaDenmark
-
Cairo UniversityCompletedIs Lower Limb Neuromotor Control Diverse in Females With PF OA Contrasted With Asymptomatic ControlsChondromalacia PatellaeEgypt
-
Sheba Medical CenterZinman College of Physical Education and Sports SciencesUnknownCartilage Diseases | ChondromalaciaIsrael
-
Gaziler Physical Medicine and Rehabilitation Education...RecruitingChondromalacia PatellaeTurkey
-
Gaziler Physical Medicine and Rehabilitation Education...CompletedChondromalacia PatellaeTurkey
-
Northwell HealthCompletedArthroplasty | Total Knee Replacement | PatellaUnited States
Clinical Trials on PST - Pulsed Signal Therapy
-
University of Lausanne HospitalsTerminated
-
Lawson Health Research InstituteBell Let's Talk Community FundCompleted
-
Yale UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Virginia Commonwealth UniversityRecruitingInformal Caregivers | Cancer SurvivorsUnited States
-
Washington University School of MedicineNurses for Newborns FoundationCompletedPost-partum DepressionUnited States
-
VA Office of Research and DevelopmentNot yet recruiting
-
University of Texas at AustinNational Institute of Mental Health (NIMH)CompletedDepressionUnited States
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH)Completed
-
PEMF Systems, Inc.Southern California Institute for Research and Education; VA Long Beach Healthcare...Not yet recruitingChronic Wounds
-
BioElectronics CorporationUnknown